Natural History Study of HIV Acquired in Infancy or Childhood

NCT00924365 | Completed

• 2 other identifiers: 07008707-C-0087
• Study Type: observational
• Target: 54
• Locations: 1 country
• Sites: 1

Brief Summary

Background:

• About 10,000 children in the United States have been living with HIV infection since birth. Little is known about the long-term effects of HIV infection and its treatment on the growth and development of these children.
• Because of their disease, many children with HIV face additional difficulties with their health, well-being and development, such as success in school and peer relationships. Objectives:
• To better understand how HIV infection and the medicines used to treat it affect the growth and development of children, adolescents and young adults who have been infected since birth or when they were very young.
• To develop ways to improve the quality of life for these individuals. Eligibility:
• HIV-infected patients who were followed by the pediatric HIV program in NCI as of December 2004, or an HIV-infected sibling of a participant. Design:
• Periodic evaluation of pubertal development; bone mineralization; body composition and fat distribution; liver, kidney and heart status; and behavioral, cognitive and academic or vocational outcome of the study group. Evaluations include the following:
• Physical examinations, including height and weight measurements and skin-fold thickness testing to measure body fat.
• Review of medical records and family history.
• Blood and urine tests, including pregnancy test in females who can bear children.
• DEXA scans (X-ray test to measure bone strength and how much fat, muscle and bone is in the body).
• Neuropsychological testing, including evaluation of language, thinking and problem-solving abilities.
• Magnetic resonance imaging (MRI): Test using a magnetic field and radio waves to examine brain structure and function.
• Oral glucose tolerance test: Blood sampling before and one time after the subject drinks a sugary solution to measure the body's ability to use sugar

Conditions

HIV Infections

Keywords

Children; AIDS; Toxicity; Development; Puberty; HIV; Pediatrics; HIV Infections

Eligibility Criteria

• Age: 6 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Known HIV disease and followed in the NCI pediatric HIV program (on an NCI protocol) as of December 2004, or an HIV-infected sibling of a participant.
• Age greater than 6 years.
• For children greater than 7 years, ability to give assent if developmentally appropriate.
• Receives care from a health care provider not affiliated with the protocol.
• HIV positive participants
• Known HIV disease, documented or believed to have been acquired during the first decade of life
• Age greater than 7 years old
• HIV negative participants
• HIV negative, documented by a negative ELISA
• Age greater than or equal to 18 years old and less than or equal to 30 years old

You may not qualify if:

• Inability or unwillingness to provide informed consent for subjects greater than or equal to 18 years, and inability or unwillingness of one parent/legal guardian to provide consent for subjects less than 18 years.
• Clinically significant, systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction) which in the judgment of the Principal Investigator would compromise the patient s ability to tolerate this study.
• Subjects with contraindication to MRI scanning. These include but are not limited to the presence of any implanted device that is incompatible with MRI.
• Subjects who cannot tolerate an MRI scan or who require sedation for MRI.
• Pregnant or lactating women.
• History of severe allergic reaction to gadolinium contrast agents.
• Estimated glomerular filtration rate less than 60 cc/min/1.73m(2).
• Inability or unwillingness to provide informed consent for subjects greater than 18 years, and inability or unwillingness of one parent/legal guardian to provide permission for subjects less than 18 years.
• Clinically significant, systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction) which in the judgement of the Principanl Investigator (or designee) would compromise the patient s ability to tolerate this study
• Age less than 18 years
• Use of metformin-containing products less than 24 hours prior to contrast administration
• History of Multiple Myeloma
• Cratinine value greater than 1.4 mg/dL
• History of significant allergic reaction to CT contrast agents
• Asthma

Sponsors & Collaborators

• National Cancer Institute (NCI): lead

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (5)

• Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR 3rd, Song LY, Dankner WM, Oleske JM; Pediatric AIDS Clinical Trials Group Protocol 219 Team. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001 Nov 22;345(21):1522-8. doi: 10.1056/NEJMoa011157.

  PMID: 11794218 BACKGROUND

• Abrams EJ, Weedon J, Bertolli J, Bornschlegel K, Cervia J, Mendez H, Lambert G, Singh T, Thomas P; New York City Pediatric Surveillance of Disease Consortium. Centers for Disease Control and Prevention. Aging cohort of perinatally human immunodeficiency virus-infected children in New York City. New York City Pediatric Surveillance of Disease Consortium. Pediatr Infect Dis J. 2001 May;20(5):511-7. doi: 10.1097/00006454-200105000-00008.

  PMID: 11368109 BACKGROUND

• Belman AL, Ultmann MH, Horoupian D, Novick B, Spiro AJ, Rubinstein A, Kurtzberg D, Cone-Wesson B. Neurological complications in infants and children with acquired immune deficiency syndrome. Ann Neurol. 1985 Nov;18(5):560-6. doi: 10.1002/ana.410180509.

  PMID: 3000281 BACKGROUND

• Unsal AB, Mattingly AS, Jones SE, Purdy JB, Reynolds JC, Kopp JB, Hazra R, Hadigan CM. Effect of Antiretroviral Therapy on Bone and Renal Health in Young Adults Infected With HIV in Early Life. J Clin Endocrinol Metab. 2017 Aug 1;102(8):2896-2904. doi: 10.1210/jc.2017-00197.

  PMID: 28531309 DERIVED

• Mattingly AS, Unsal AB, Purdy JB, Gharib AM, Rupert A, Kovacs JA, McAreavey D, Hazra R, Abd-Elmoniem KZ, Hadigan C. T-cell Activation and E-selectin Are Associated With Coronary Plaque in HIV-infected Young Adults. Pediatr Infect Dis J. 2017 Jan;36(1):63-65. doi: 10.1097/INF.0000000000001354.

  PMID: 27749650 DERIVED

MeSH Terms

Conditions

HIV Infections; Acquired Immunodeficiency Syndrome

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases; Slow Virus Diseases

Study Officials

• Rohan Hazra, M.D.

  National Cancer Institute (NCI)

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Sponsor Type: NIH

Study Record Dates

• First Submitted: June 17, 2009
• First Posted: June 18, 2009
• Study Start: February 1, 2007
• Study Completion: April 22, 2014
• Last Updated: December 17, 2019

Record last verified: 2014-04-22

Locations

US (1)